http://www.reuters.com/article/idCNSGE6A409Z20101105?rpc=44
Nov 5 (Reuters) - Shares of DexCom Inc (DXCM.O) fell as much as 29 percent on Friday, a day after the company said the U.S. health regulator had asked for additional data related to four of its products awaiting approval.
"The regulatory delays will impact the timing of milestone payments from the company's strategic partners, which may result in DexCom needing to raise additional capital to fund the business," Wiliam Blair & Co analyst Ben Andrew said.
Hmmm... That's not good. Interesting.
ReplyDelete